Indeed, revisited CLL-IPI combining both high- and low-VAF TP53 mutations significantly better discriminated high-risk patients than standard CLL-IPI, which exclusively considered high-VAF TP53 mutations (20, 23, 35). The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.